Unite Us and Ride Health Partner to Improve Access to Transportation Services for New Yorkers The Collaborative Initiative with Social Care Networks Will Overcome Obstacles to Vital Services Following New York State's Approval of the 1115 Medicaid Waiver See more here
Read More
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile See more here
Read More
"Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024" See more here
Read More
SIRPant Immunotherapeutics (now BobcatBio) Strengthens Board of Directors with Appointment of Roger Sawhney, M.D. See more here
Read More
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries See more here
Read More
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform - Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - Zentalis to receive up-front payment of $35 million in cash…
Read More
Immunome Appoints Phil Roberts as Chief Technical Officer See more here
Read More
Immunome Appoints Carol A. Schafer to Board of Directors See more here
Read More
Immunome to Acquire Antibody-Related Assets and Materials from Atreca See more here
Read More
SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors See more here
Read More